IP Library Granted Patent US 10,067,131
Granted Patent B2
US 10,067,131 · App. 14/710,962 · Granted Sep 4, 2018

Fragment ligated inhibitors selective for the polo box domain of PLK1

Inventors: Campbell McInnes (Irmo, SC); Doaa Boshra Farag (Cairo, EG)
Assignee: University of South Carolina
G01N33/573A61K38/06A61K38/08A61K47/48023A61K47/48038A61K47/48061C07K5/081C07K7/06C12N9/12C12N9/16C12Y207/11021G06F19/18C07K2317/34C12Y301/03048G01N2333/912G01N2500/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,067,131
App. No.
14/710,962
Granted
Sep 4, 2018
Kind
B2
Abstract

Methods for developing non-peptidic inhibitors that target the polo-box domain of PLK1 proteins are described. Methods include developing structure activity relationships for peptidic inhibitors followed by development of non-peptide fragment alternatives for portions of the peptide inhibitors. The non-peptide fragment can provide similar structure activity relationship as the replaced peptide. Fragment alternatives to key binding determinants are identified in an iterative computational and synthetic process facilitated through understanding of the peptide structure-activity relationships. The approach is informed by peptide structure-activity data obtained through synthesis and testing of truncated and mutated analogs of known PBD binding motifs.

Claims (5)

1. A fragment ligated inhibitor that is selective to a polo box domain of a PLK1 protein, the fragment ligated inhibitor comprising a peptide fragment and a non-peptide fragment, the peptide fragment comprising S[pT]PNGL (SEQ ID NO: 12), LLCS[pT]AI (SEQ ID NO: 23), S[pT]AI (SEQ ID NO: 24) or S[pT]A (SEQ ID NO: 25), the peptide fragment including no additional peptide residues on the N-terminus of the peptide fragment, the non-peptide fragment comprising a 4-alkyl benzoic acid, a 4-alkylthio benzoic acid, a 4-alkylamino benzoic acid, or a 4-alkoxy benzoic acid, wherein the non-peptide fragment is directly bonded to the N-terminus of the peptide fragment.

2. The fragment ligated inhibitor according to claim 1 , wherein the non-peptide fragment comprises an unsubstituted alkyl group.

3. The fragment ligated inhibitor according to claim 2 , wherein the non-peptide fragment comprises an unsubstituted straight chain alkyl group.

4. The fragment ligated inhibitor according to claim 1 , wherein the non-peptide fragment comprises ethyl-benzoic acid, propyl benzoic acid, or butyl-benzoic acid.

5. The fragment ligated inhibitor according to claim 1 , wherein the non-peptide fragment comprises propylamino benzoic acid, methylamino benzoic acid, methylthio benzoic acid, ethyoxy benzoic acid, or propoxy benzoic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: MCINNES, CAMPBELL; FARAG, DOAA BOSHRA
To: UNIVERSITY OF SOUTH CAROLINA
Reel/Frame 035628/0290 →
Continuity (4)
Continuation 13365707 · Feb 3, 2012
Provisional Application 61627788 · Oct 18, 2011
Provisional Application 61462577 · Feb 4, 2011
Related Publication 20150315555A1 · Nov 5, 2015
Cited By (2)
US 12,415,822 US 12,559,733